Close Menu

diabetes

The effort aims to identify a suite of markers that could aid in management of type II diabetes and related conditions like retinopathy and kidney damage.

The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.

The core technology uses proximity-ligated amplification and the firm will build it into tests for type I diabetes as well as highly multiplexed assays.

Pages